Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: An extension study

Pharmacopsychiatry

Volumn 45, Issue 5, 2012, Pages 196-203

  Schoemaker, J ^a,b   Stet, L ^b   Vrijland, P ^b   Naber, D ^c   Panagides, J ^d,e   Emsley, R ^f  

^a Clinical Research Neuroscience   (Netherlands)

^b NV ORGANON   (Netherlands)

^c UNIVERSITY OF HAMBURG   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Merck ^*

^f STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

asenapine; olanzapine; schizoaffective disorder; schizophrenia; tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; ASENAPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; OLANZAPINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; COMPARATIVE EFFECTIVENESS RESEARCH; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHARMACOVIGILANCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TIME; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84863931968     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1301310     Document Type: Article

References (15)

1. Saha S, Chant D, Welham J et al. A systematic review of the prevalence of schizophrenia. PLoS Med: 2005; 2 e141
2. Perala J, Suvisaari J, Saarni S I et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry: 2007; 64 19 28 (Pubitemid 46041735)
3. Weiden P J. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract: 2007; 13 13 24 (Pubitemid 46148428)
4. Tandon R, Jibson M D. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int J Psychiatry Clin Pract: 2005; 9 204 212 (Pubitemid 41499390)
5. Tandon R, Fleischhacker W W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res: 2005; 79 145 155 (Pubitemid 41457255)
6. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother: 2009; 10 1917 1928
7. ® (asenapine sublingual tablets) Full Prescribing Information, Schering Corporation, a subsidiary of Merck & Co., Inc. Whitehouse Station NJ: 2010
8. European Medicines Agency. Sycrest (asenapine) Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 001177/human-med-001379.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124&jsenabled=true. Accessed September 28, 2010
9. Kane J M, Cohen M, Zhao J et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol: 2010; 30 1 10
10. Potkin S G, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry: 2007; 68 1492 1500 (Pubitemid 350073395)
11. Schoemaker J, Naber D, Vrijland P et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry: 2010; 43 138 146
12. Strauss J S, Carpenter W T Jr. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch Gen Psychiatry: 1972; 27 739 746
13. Strauss J S, Carpenter W T Jr. Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch Gen Psychiatry: 1977; 34 159 163 (Pubitemid 8025013)
14. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs: 2008; 13 479 495
15. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: 2010; 3 CD006654